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Background: In the United Kingdom (UK), in recent 
influenza seasons, children are offered a quadrivalent 
live attenuated influenza vaccine (LAIV4), and eligible 
adults mainly trivalent inactivated vaccine (TIV). Aim: 
To estimate the UK end-of-season 2017/18 adjusted 
vaccine effectiveness (aVE) and the seroprevalence 
in England of antibodies against influenza viruses 
cultured in eggs or tissue. Methods: This observa-
tional study employed the test-negative case–control 
approach to estimate aVE in primary care. The pop-
ulation-based seroprevalence survey used residual 
age-stratified samples. Results: Influenza viruses 
A(H3N2) (particularly subgroup 3C.2a2) and B (mainly 
B/Yamagata/16/88-lineage, similar to the quadriva-
lent vaccine B-virus component but mismatched to 
TIV) dominated. All-age aVE was 15% (95% confi-
dence interval (CI): −6.3 to 32) against all influenza; 
−16.4% (95% CI: −59.3 to 14.9) against A(H3N2); 24.7% 
(95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 
to 82.9) against A(H1N1)pdm09. For 2–17 year olds, 
LAIV4 aVE was 26.9% (95% CI: −32.6 to 59.7) against 
all influenza; −75.5% (95% CI: −289.6 to 21) against 
A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 
90.3% (95% CI: 16.4 to 98.9) against A(H1N1)pdm09. 
For ≥ 18 year olds, TIV aVE against influenza B was 1.9% 
(95% CI: −63.6 to 41.2). The 2017 seroprevalence of 
antibody recognising tissue-grown A(H3N2) virus was 
significantly lower than that recognising egg-grown 
virus in all groups except 15–24 year olds. Conclusions: 
Overall aVE was low driven by no effectiveness against 
A(H3N2) possibly related to vaccine virus egg-adaption 
and a new A(H3N2) subgroup emergence. The TIV was 
not effective against influenza B. LAIV4 against influ-
enza B and A(H1N1)pdm09 was effective.
Introduction
The United Kingdom (UK) has a long-standing selective 
influenza immunisation programme offering inactivated 
vaccine to persons ≥ 65 years of age and those aged 
6 months to 64 years of age with an underlying clinical 
risk factor. Following advice from the Joint Committee of 
Vaccination and Immunisation (JCVI), the UK started a 
phased introduction of a universal childhood influenza 
vaccine programme in 2013/14 [1]. By 2017/18, all chil-
dren 2–8 years of age across the UK were being offered 
quadrivalent live attenuated influenza vaccine (LAIV4), 
with uptake higher than the previous season in tar-
geted cohorts [2]. In addition, in England, besides chil-
dren 2–8 years of age, all remaining children of primary 
school age (9–11 years of age) in discrete geographi-
cal pilots were offered LAIV4. Scotland and Northern 
Ireland also offered LAIV4 to all children of primary 
school age (including 9–11 years of age). A B/Yamagata 
lineage virus (B/Phuket/3073/2013-like virus) and a B/
Victoria lineage virus (B/Brisbane/60/2008-like virus) 
were contained in the season’s quadrivalent inacti-
vated influenza vaccine (QIV) and LAIV4, but not in 
the trivalent inactivated influenza vaccine (TIV), which 
contained only the B/Victoria lineage vaccine virus [3].
Several areas of concern in relation to vaccine effec-
tiveness (VE) have emerged in recent seasons. Firstly, 
although the UK has found evidence of relatively good 
LAIV VE and continues to recommend its preferen-
tial use [4], in the United States (US) where there has 
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been a longstanding paediatric influenza vaccination 
programme using both LAIV and inactivated influ-
enza vaccine (IIV), reduced LAIV VE against influenza 
A(H1N1)pdm09 was reported by the US Centers for 
Disease Control and Prevention (CDC) [5]. This led to 
a recommendation from the Advisory Committee on 
Immunization Practice (ACIP) that LAIV should not be 
used in the US from 2016 until 2018. Questions were 
raised about what might explain these observations, 
such as reduced replicative ability of the A(H1N1)pdm09 
strain [6]. Secondly, reductions in IIV VE particularly in 
older persons, a highly vaccinated population in the 
UK, have been previously noted, particularly against 
influenza A(H3N2), with several explanations prof-
fered, including egg adaption of vaccine viruses, which 
may affect their antigenicity [7]. Finally, the majority 
of vaccinated adults at clinical risk were receiving TIV 
rather than QIV in the UK programme. Mismatches of 
the vaccine B-lineage virus compared with the predom-
inant circulating influenza B virus lineage have been 
reported, which raises questions on the optimal vac-
cine to use in influenza vaccine programmes [4].
The 2017/18 influenza season in the UK was charac-
terised by the co-circulation of both influenza A(H3N2) 
and influenza B, with some circulation of A(H1N1)
pdm09. A large number of respiratory outbreaks in 
highly vaccinated populations were reported, particu-
larly in long-term care facilities. In addition, increased 
admissions to hospital and excess mortality especially 
among older adult age groups were noted despite vac-
cine uptake levels of > 70% in ≥ 65 year olds [8]. The UK 
has a well-established system to monitor influenza 
VE each season based upon sentinel swabbing in pri-
mary care [9]. This paper presents the end-of-season 
2017/18 VE findings for laboratory-confirmed infection 
in primary care across all age groups, with a focus on 
LAIV4 in children and IIV in adult age groups.
Methods
Design of the study
The test-negative case–control (TNCC) design was 
used to estimate VE, with the study undertaken in the 
registered population of five sentinel general prac-
tice surveillance networks across the UK, all of which 
undertake respiratory swabbing according to a stand-
ard protocol. Details of these schemes have been out-
lined previously [4]. The five sentinel schemes are: the 
Royal College of General Practitioners (RCGP) Research 
and Surveillance Centre (RSC) network, the Public 
Health England (PHE) Specialist Microbiology Network 
(SMN) and the national sentinel schemes of Northern 
Ireland, Scotland and Wales.
Figure 1
Swabbing results of patients with influenza-like illness in primary care in the United Kingdom, October 2017–April 2018 
(n = 3,992 patients swabbed)
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1. date of sample prior to 1 Oct 2017 (n = 35)
2. LAIV strain (n = 4)
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LAIV4: quadrivalent live attenuated influenza vaccine; NI: Northern Ireland national sentinel scheme; RCGP: Royal College of General 
Practitioners’ Research and Surveillance Centre; SMN: Public Health England Specialist Microbiology Network.
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Table 1
Characteristics of influenza A and B cases and controls, United Kingdom, October 2017–April 2018 (n = 3,080)
Characteristics
Control 
 
(n = 1,768)
Cases by influenza type (and subtype if known) 
 
(n = 1,315)a
Total p value
B 
 
(n = 766)
A(H1N1) 
 
(n = 96)
A(H3N2) 
 
(n = 431)
A (unknown) 
 
(n = 22)
Age in years
0–1 153 7 7 8 0 175
 < 0.0001
2–11 212 71 22 58 0 363
12–17 98 66 5 28 4 201
18–44 587 267 31 143 7 1,035
45–64 447 261 22 122 10 862
≥ 65 270 94 9 72 1 446
Missing 1 0 0 0 0 1
Sex
Female 1,083 416 49 247 14 1,809
0.004Male 671 346 47 184 8 1,256
Missing 14 4 0 0 0 18
Database
Northern Ireland 99 85 6 66 8 264
< 0.0001
RCGP 1,203 484 76 189 0 1,952
SMN 86 51 6 16 4 163
Scotland 266 79 5 135 10 495
Wales 114 67 3 25 0 209
Risk group
No 1,075 553 62 258 11 1,959
< 0.0001Yes 545 139 25 137 7 853
Missing 148 74 9 36 4 271
Onset to swab in days
0–1 240 78 13 85 5 421
< 0.00012–4 867 458 59 252 10 1,646
5–7 661 230 24 94 7 1,016
Vaccination status
Unvaccinated 1,273 594 78 280 18 2,243
< 0.0001Vaccinated (14–91 days ago) 297 75 10 78 2 462
Vaccinated (> 91 days ago) 198 97 8 73 2 378
Month of event
October 270 2 0 4 2 278
< 0.0001
November 310 27 4 18 2 361
December 344 169 19 125 4 661
January 509 374 39 167 10 1,099
February 206 147 24 67 3 447
March 110 45 8 48 1 212
April 19 2 2 2 0 25
Pilot area (SMN and RCGP RSC only)
No 1,391 599 84 226 3 2,303
< 0.0001
Yes 377 167 12 205 19 780
Vaccination status (for 2–17 year olds only)
Unvaccinated 252 127 26 62 4 471
0.52Injection (QIV) 9 1 0 1 0 11
Intranasal/LAIV4 49 9 1 23 0 82
LAIV4: quadrivalent live attenuated influenza vaccine; QIV: quadrivalent inactivated influenza vaccine; RCGP RSC: Royal College of General 
Practitioners’ Research and Surveillance Centre scheme; SMN: Public Health England Specialist Microbiology Network.
a While the study comprised 1,312 cases of influenza, 1,315 are presented in the table, because there were two cases of infection with multiple 
types or subtypes. One of these cases was infected by influenza A(H1N1)pdm09 and, in addition A(H3N2) and B (thus accounting, for 
two additional cases in the total number of cases by type/subtype) and the other was infected by A(H1N1)pdm09 and also A(H3N2) (thus 
accounting for one additional case in the total number of cases by type/subtype).
A total of 149 samples had date of vaccination imputed.
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Table 2
Details of vaccination status for key demographic and clinical variables, United Kingdom, October 2017–April 2018 
(n = 3,080)
Characteristics
Not vaccinated 
 
(n = 2,242)
Vaccinated 
 
(n = 838)
Total p value
Age in years
< 2 172 3 175
 < 0.0001
2–11 270 93 363
12–17 187 14 201
18–44 886 148 1,034
45–64 619 243 862
≥ 65 108 336 444
Missing 0 1 1
Sex
Female 1,279 527 1,806
0.004Male 948 308 1,256
Missing 15 3 18
Surveillance scheme
Northern Ireland 206 58 264
0.002
RCGP RSC 1,380 571 1,951
SMN 116 47 163
Scotland 371 122 493
Wales 169 40 209
Risk group
No 1,665 294 1,959
< 0.0001Yes 376 474 850
Missing 201 70 271
Onset to swab in days
0–1 315 106 421
0.492–4 1,185 458 1,643
5–7 742 274 1,016
Pilot area (RCGP RSC and SMN only)
No 1,650 652 2,302
0.014
Yes 592 186 778
Month of event
October 244 34 278
< 0.0001
November 290 69 359
December 478 183 661
January 773 326 1,099
February 309 138 447
March 136 75 211
April 12 13 25
Cases infected with strains characterised by sequencing/phylogenetic analysis
Influenza A
H3N2 - 3C.2a3 - subgroup 2 1 1 2
0.02
H3N2 - 3C.2a2 - subgroup 3 49 64 113
H3N2 - 3C.2a - subgroup NA 1 0 1
H3N2 - 3C.2a1a - subgroup 4 3 0 3
H3N2 - 3C.2a1b - subgroup 5 18 7 25
H3N2 - 3C.2a1 - subgroup NA 8 3 11
H3N2 - 3C.3a 4 3 7
H1N1 – 6B.1 clade 35 12 47 N/A
Influenza B
B/Yamagata 300 106 406
0.26
B/Victoria 0 1 1
RCGP RSC: Royal College of General Practitioners’ Research and Surveillance Centre scheme; SMN: Public Health England Specialist 
Microbiology Network.
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The study took place from 1 October 2017 – when res-
piratory swabbing was started – until 15 April 2018. The 
study population was patients presenting to their gen-
eral practitioner (GP) during the study period with an 
acute influenza-like illness (ILI), who the GP obtained 
consent from and swabbed during the consultation. 
A case of ILI was defined as an individual who pre-
sented with an acute respiratory illness with physician-
diagnosed fever or complaint of feverishness in the 
previous 7 days [9]. The combination of acute onset, 
cough and systemic symptoms (fever, headache, myal-
gia etc.) was recommended as a guide to diagnosis. 
Participating GPs were asked to invite persons pre-
senting with ILI to provide a swab for diagnosis, with 
swabbing undertaken regardless of vaccination status. 
Cases were patients who tested positive for seasonal 
influenza A or B virus by real-time PCR. Controls were 
patients with the same symptoms who tested negative 
for influenza A or B virus.
During the consultation, the GP completed a standard 
questionnaire. This collected demographic (age and 
sex), clinical (date of onset and history of fever) and 
epidemiological information from patients including 
vaccination status. Vaccine history, including date of 
vaccination was obtained mainly from patient records. 
Vaccine type (LAIV4-intranasal; IIV injectable) was 
specified on the form. Additional information was col-
lected for those ≥ 18 years of age on whether vaccina-
tion was with QIV or TIV. Persons in the study were 
categorised according to Department of Health defined 
risk categories for influenza vaccination [2]. High risk 
was determined by the presence of well recognised 
risk morbidities recorded in the electronic health 
record for the patient concerned [2]. In addition, it was 
noted whether the general practice was in a pilot area 
for England-based paediatric immunisation schemes, 
where all primary school age children were offered 
LAIV4 vaccine.
Patients were defined as vaccinated if they were 
reported to have received the 2017/18 seasonal vac-
cine at least 14 days before first onset of symptoms. 
Patients were excluded if they were vaccinated less 
than 14 days before symptom onset. If date of vaccina-
tion was unknown it was assumed to be 15/10/2017, 
which was the median of all known vaccination dates 
this season: the approach used in prior seasons [4].
Registered patients were excluded if they (or their par-
ent/guardian) had expressed a wish to be; or the prac-
tice used one of the codes that indicate the patient may 
not want to share data (e.g. no consent for electronic 
record sharing). The opt out of sharing data was 2.25%.
Detection and characterisation of influenza 
viruses in sentinel-surveillance- and non-
sentinel samples
Combined throat and nose swabs taken from GPs are 
sent from the sentinel GP surveillance networks to their 
usual laboratory. Influenza laboratory confirmation 
was undertaken using comparable real-time PCR 
methods able to detect circulating influenza A and B 
viruses [10]. All laboratories sent influenza virus posi-
tive samples to the reference laboratories for further 
characterisation.
Isolation of Influenza viruses was attempted from all 
suitable PCR positive samples, from both sentinel GP 
practices and also non-sentinel schemes using Madin–
Darby canine kidney epithelial (MDCK) cells or MDCK 
cells containing the cDNA of human 2,6-sialtransferase 
(SIAT1) cells [11,12].
Virus isolates with a haemagglutination titre ≥ 40 were 
characterised antigenically using post-infection ferret 
antisera in haemagglutination inhibition (HI) assays, 
with guinea pig (A(H3N2) viruses) or turkey (influenza 
B viruses) red blood cells [12]. Reference virus strains 
used for HI assays included 2017/18 vaccine strains [3] 
and other A(H3N2) and influenza B reference strains 
grown in embryonated chicken eggs and tissue culture 
cells.
Nucleotide sequencing of the haemagglutinin (HA) 
gene of a subset of influenza A(H3N2) and influenza B 
viruses selected to be representative of the range of the 
patients’ age, date of sample collection, geographical 
location and antigenic characterisation of the virus iso-
late, if performed, was undertaken. Phylogenetic trees 
of the HA gene of A(H3N2) and influenza B viruses were 
constructed with a neighbour-joining algorithm avail-
able in the Molecular Evolutionary Genetics Analysis 
(MEGA) 7 software (http://www.megasoftware.net) 
[13].
HA sequences from reference strains used in the phy-
logenetic analysis were obtained from the EpiFlu data-
base of the Global Initiative on Sharing All Influenza 
Data (GISAID) (www.gisaid.org) (Supplement). The HA 
sequences generated for this study and used in the 
phylogenetic analysis, were deposited in GISAID under 
the following accession numbers: A(H3N2) viruses: 
EPI1112284, EPI1112292, EPI1112308, EPI1112348, 
EPI1112444, EPI1112484, EPI1112492, EPI1112500, 
EPI1112532, EPI1112596, EPI1112612, EPI1112620, 
EPI1112636, EPI1112652, EPI1112782, EPI1112788, 
EPI1139067, EPI1139075, EPI1139123, EPI1139155, 
EPI1139339, EPI1139347, EPI1139379, EPI1139490, 
EPI1139578, EPI1139646, EPI1139681, EPI1144477, 
EPI1144533, EPI1144549, EPI1144573, EPI1144589, 
EPI1144613, EPI1144661, EPI1144701, EPI1144709, 
EPI1144725, EPI1144845, EPI1144885, EPI1144925, 
EPI1144957, EPI1144965, EPI1144997, EPI1152027, 
EPI1152059, EPI1152227, EPI1152251, EPI1152275, 
EPI1152291, EPI1152451, EPI1152507, EPI1152623, 
EPI1152631, EPI1152687, EPI1152695, EPI1152711, 
EPI1152734, EPI1152736, EPI1152756, EPI1173388, 
EPI1173668, EPI1173700, EPI1173732, EPI1173756, 
EPI1173789, EPI1173979, EPI1173993, EPI1173999, 
EPI1174019; influenza B viruses: EPI1112540, 
EPI1112572, EPI1112580, EPI1112765, EPI1112790, 
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Figure 2
Phylogenetic analysis of the haemagglutinin sequences of influenza A(H3N2) viruses detected in the United Kingdom, July 
2017–April 2018a
3C.2a1b
3C.2a
3C.3a
A/England/80260473/2018
A/England/75280376/2017
A/England/75160399/2017
A/England/74920383/2017
A/England/74340637/2017
A/England/74300448/2017
A/England/75020491/2017
A/England/73880604/2017
A/England/74660583/2017
A/England/74600617/2017
A/England/75260826/2017
A/England/80160674/2017
A/England/80220576/2018
A/England/80180647/2017
A/England/80280646/2018
A/England/74620549/2017
A/England/75260318/2017
A/England/74500548/2017
A/England/75240075/2017
A/England/72840639/2017
A/England/73580521/2017
A/England/74920384/2017
A/England/73160333/2017
A/England/74080448/2017
A/England/73980577/2017
A/England/75260833/2017
A/England/80200502/2018
A/England/80220578/2018
A/England/74320429/2017
A/Scotland/63440583/2016
A/Singapore/Infimh -16-0019/2016
A/England/75120448/2017
A/England/75260820/2017
A/Bolzano/7/2016
A/England/75240051/2017
A/England/80340463/2018
A/England/73300573/2017
A/England/75160393/2017
A/England/74480500/2017
A/England/75120454/2017
A/England/75040599/2017
A/England/80180628/2017
A/England/80200464/2018
A/England/75260839/2017
A/England/80220597/2018
A/England/75060551/2017
A/England/75020484/2017
A/England/75160387/2017
A/England/80200461/2017
A/England/80260483/2018
A/England/80280654/2018
A/England/120/2017
A/England/80340461/2018
A/England/74680313/2017
A/England/75260814/2017
A/England/75160360/2017
A/England/80320668/2018
A/England/80260505/2017
A/England/75100513/2017
A/England/75260312/2017
A/England/75260997/2017
A/England/75060561/2017
A/England/75260832/2017
A/England/75280703/2017
A/England/74680316/2017
A/England/74940548/2017
A/England/72980505/2017
A/England/73520178/2017
A/England/80120218/2018
A/England/75160395/2017
A/England/74000497/2017
A/New Caledonia/71/2014 (LAIV)
A/Hong Kong/4801/2014
A/England/73660229/2017
A/England/74380294/2017
A/Samara/73/2013
A/England/75020489/2017
A/Switzerland/9715293/2013 
A/Texas/50/2012
0.002
E62G
T135K( -CHO)
T135N( -/+CHO)
T135K
N121K
T131K
R142K
R261Q
N122D( -CHO)
S262N
N31S
D53N
R142G
S144R
N171K
I192T
Q197H
A304T
S442A
K92R
H311Q
N171K
I406V
G484E
V309I
R142G
A212T
E62K
N121K
S144K
T135K( -CHO)
R150K
R261QT128A
A138S
F159S
T160K
H311Q
K326R
R142G
3C.2a1a
3C.2a2
3C.2a3
3C.2a4
LAIV: live attenuated influenza vaccine ; QIV: quadrivalent inactivated influenza vaccine; TIV: trivalent inactivated influenza vaccine.
a The sequences are obtained from all sources (i.e. sentinel surveillance and non-sentinel schemes) so some of the sequences are from as 
early as July 2017.
The H3 haemagglutinin sequences obtained in England in 2017 and 2018 are depicted on the tree. The vaccine strains (A/
HongKong/4801/2014 for TIV and QIV; A/NewCaledonia/71/2014 for LAIV) are boxed; reference viruses are represented in italics. Amino 
acid substitutions are depicted at the nodes. ‘-/+CHO’ indicates the addition or deletion of a potential glycosylation site. The names of the 
subclades and clusters to which the sequences belong to are indicated on the right hand side of the tree. The scale is proportional to number 
of nucleotide substitutions per site.
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EPI1112792, EPI1112798, EPI1139027, EPI1139163, 
EPI1139203, EPI1139299, EPI1139427, EPI1139482, 
EPI1139514, EPI1139538, EPI1139586, EPI1139666, 
EPI1144501, EPI1144509, EPI1144565, EPI1144605, 
EPI1144629, EPI1144637, EPI1144741, EPI1144797, 
EPI1144837, EPI1144909, EPI1144917, EPI1145005, 
EPI1152075, EPI1152091, EPI1152147, EPI1152155, 
EPI1152307, EPI1152403, EPI1152411, EPI1152483, 
EPI1152491, EPI1152523, EPI1152639, EPI1152679, 
EPI1152703, EPI1152745, EPI1152751, EPI1152760, 
EPI1173244, EPI1173284, EPI1173316, EPI1173340, 
EPI1173348, EPI1173356, EPI1173372, EPI1173420, 
EPI1173428, EPI1173444, EPI1173468, EPI1173476, 
EPI1173484, EPI1173516, EPI1173532, EPI1173556, 
EPI1173580, EPI1173676, EPI1173983, EPI1173997, 
EPI1199126, EPI811586.
Seroepidemiological survey
Annual sero-surveys were carried out in England using 
residual sera collected and submitted to the PHE 
Sero-epidemiology Unit (SEU) during the 2016 and 
2017 summers. The PHE SEU archive is an opportunis-
tic collection of residual serum samples from routine 
microbiological testing, submitted voluntarily each 
year from laboratories throughout England, with sam-
ples anonymised and permanently unlinked from any 
patient identifying information with only age, sex, date 
of collection and contributing laboratory retained. A 
total of 780 residual sera from the SEU were collected 
during the 2017 summer period (after the previous and 
before start of the current influenza season) and 1,000 
samples in summer 2016. Samples were randomly 
selected with constraints to provide an even distribu-
tion by age and region. The sample size was chosen to 
enable reasonable precision of estimates (95% confi-
dence interval (CI) width less than +/− 10%) within each 
age group.
Laboratory analysis was focused on detection of anti-
body to influenza A(H3N2) and B/Yamagata viruses. 
Serum samples were analysed for presence of A(H3N2) 
antibody to representative seasonal influenza strains 
as indicated by the vaccine composition for 2017/18 
using guinea pig erythrocytes for A(H3N2) and turkey 
erythrocytes for influenza B as previously described. 
Antigen was grown in eggs and tissue culture (MDCK 
cells) to examine the issue of potential egg adaptation 
and the influenza B antigen diethyl-ether extracted.
Sera were analysed in single titrations in 96-well for-
mat by performing doubling serum dilutions starting at 
1:10 up to 1:1,280, with virus input adjusted to 4 hae-
magglutination forming units (4 HAU).
Figure 3
Frequency of H3N2 haemagglutinin genetic groups by month, England, September 2017–April 2018 (n = 605)`
3C2a3 (subgroup 2) 3C2a4 (subgroup 1) 3C2a1b (subgroup 5)
3C2a2 (subgroup 3) 3C2a1 (subgroup 4) 3C3a
4%
21%
72%
2%
1%
33%
11%
56%
September (n = 10)
January (n = 224)
October (n = 20)
February (n = 102)
15%
5%
55%
20%
5%
11%
80%
1%
8%
November (n = 29)
March (n = 100)
14%
48%
31%
7%
1%
10%
81%
8%
December (n = 110)
April (n = 10)
2%
36%
58%
3%
1%
80%
20%
Genetic groups definition as suggested by NextFlu/Crick Feb 2018 (in brackets, previous definition suggested by NextFlu/ECDC Sept 2017).
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Figure 4
Phylogenetic analysis of the haemagglutinin sequences of influenza B viruses detected in the United Kingdom, July 2017–
April 2018
B/England/106/2017
B/England/151/2017
B/England/20/2018
B/England/134/2017
B/England/15/2018
B/England/80160864/2018
B/England/43/2018
B/England/42/2018
B/England/168/2017
B/England/75120474/2017
B/England/128/2017
B/England/127/2017
B/England/123/2017
B/England/105/2017
B/England/80200301/2018
B/England/101/2017
B/England/60/2018
B/England/130/2017
B/England/80220815/2018
B/England/75260842/2017
B/England/189/2017
B/England/136/2017
B/England/61/2018
B/England/17/2018
B/England/14/2018
B/England/80180465/2018
B/England/107/2017
B/England/173/2017
B/England/129/2017
B/England/72980504/2017
B/England/16/2018
B/England/72900412/2017
B/England/148/2017
B/England/82/2017
B/England/100/2017
B/England/135/2017
B/England/67/2017
B/England/70/2017
B/England/124/2017
B/England/75260824/2017
B/England/161/2017
B/England/1/2018
B/England/74/2017
B/England/73920680/2017
B/England/80200298/2018
B/England/192/2017
B/England/2/2018
B/England/104/2017
B/England/40/2018
B/England/80220584/2018
B/England/183/2017
B/England/160/2017
B/England/80200280/2018
B/England/109/2017
B/England/41/2018
B/England/181/2017
B/England/108/2017
B/England/80160501/2018
B/England/152/2017
B/England/73/2017
B/England/59/2018
B/England/75120472/2017
B/England/80220591/2018
B/England/729/2016
B/England/73660241/2017
B/Phuket/3073/2013
B/Wisconsin/01/2010
B/Bangladesh/3333/2007
B/Massachusetts/02/2012
B/Estonia/77391/2013
B/Yamagata/16/88
B/Victoria/2/87
B/HongKong/330/2001
B/Malaysia/2506/2004
B/Brisbane/60/2008 
B/Odessa/3886/2010
B/England/66/2017
B/England/71/2017
B/England/27/2018 ∆
B/England/103/2017  ∆
B/England/159/2017 ∆
0.01
B/Yamagata lineage 
B/Victoria lineage
N116K
K298E
E312K
L172Q
M251V
N202SS150I
N165Y
G229D
Clade 3
Clade 2
D232N (+CHO)
Clade 1A
Clade 1B
Clade 1A
N75K
N165K
S172P I117V
N129D
V146I
LAIV: live attenuated influenza vaccine; QIV: quadrivalent inactivated influenza vaccine; TIV: trivalent inactivated influenza vaccine.
a The sequences are obtained from all sources (i.e. sentinel surveillance and non-sentinel schemes) so some of the sequences are from as 
early as July 2017.
The influenza B haemagglutinin sequences obtained in England in 2017 and 2018 are depicted on the tree. The vaccine strains (B/
Brisbane/60/2008 for TIV, QIV and LAIV; B/Phuket/3073/2013 for QIV and LAIV) are boxed; reference viruses are represented in italics. Amino 
acid substitutions are depicted at the nodes. ‘+CHO’ indicates the addition of a potential glycosylation site. The names of the clades to which 
the sequences belong to are indicated on the right hand side of the tree. The scale is proportional to number of nucleotide substitutions per 
site.
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Table 3
Vaccine effectiveness estimates for influenza by subtype, clade, age group and vaccine type, United Kingdom, October 
2017–April 2018 (n = 3,080)
Characteristics
Cases Controls Crude VE 
 
(95% CI)
Adjustedc VE 
 
(95% CI)Vaccinateda Unvaccinated Vaccinatedb Unvaccinated
Influenza A and B, by age group in years and vaccine type for 2–17 year olds
All age 343 969 495 1,273 9.0 (−6.9 to 22.5) 15.0 (−6.3 to 32.0)
2–17 (QIV) 2 213 9 244 NR NR
2–17 (LAIV4) 33 213 49 244 22.9 (−24.4 to 52.2) 26.9 (−32.6 to 59.7)
18–64 166 696 225 809 14.2 (−7.4 to 31.5) 12.2 (−16.8 to 34.0)
≥ 65 136 38 201 70 −24.6 (−95.7 to 20.6) 10.1 (−54.8 to 47.8)
Influenza A by age group in years and vaccine type for 2–17 year olds
All age 172 375 495 1,273 −18.0 (−45.3 to 4.2) 4.5 (−27.4 to 28.5)
2–17 (QIV) 1 86 9 244 NR NR
2–17 (LAIV4) 24 86 49 244 −39.0 (−140.1 to 19.6) −1.8 (−108.1 to 50.2)
18–64 76 258 225 809 −5.9 (−42.3 to 21.2) 4.4 (−39.9 to 34.6)
≥ 65 65 16 201 70 −41.5 (−160.6 to 23.2) 10.3 (−82.1 to 55.8)
Influenza A(H3N2) by age group in years and vaccine type for 2–17 year olds
All age 151 280 495 1,273 −38.7 (−73.4 to −10.9) −16.4 (−59.3 to 14.9)
2–17 (QIV) 1 59 9 244 NR NR
2–17 (LAIV4) 23 59 49 244 −94.1 (−243.7 to −9.6) −75.5 (−289.6 to 21)
18–64 67 198 225 809 −21.7 (−66.5 to 11.1) −14.7 (−72.7 to 23.8)
≥ 65 57 15 201 70 −32.3 (−148.6 to 29.6) 16.8 (−74.2 to 60.3)
Influenza A(H1N1)pdm09 by age group in years and vaccine type for 2–17 year olds
All age 18 78 495 1,273 40.7 (−0.1 to 64.8) 66.3 (33.4 to 82.9)
2–17 (QIV) 0 23 9 244 NR NR
2–17 (LAIV4) 1 23 49 244 78.3 (−64.1 to 97.1) 90.3 (16.4 to 98.9)
18–64 6 47 225 809 54.1 (−8.7 to 80.6) 69.1 (11.4 to 89.2)
≥ 65 8 1 201 70 NR NR
Influenza B by age group in years and type of vaccine
All age 172 594 495 1,273 25.5 (9.1 to 39.0) 24.7 (1.1 to 42.7)
2–17 (QIV) 1 127 9 244 NR NR
2–17 (LAIV4) 9 127 49 244 64.7 (25.9 to 83.2) 60.8 (8.2 to 83.3)
18–64 90 438 225 809 26.1 (3.2 to 43.6) 18.2 (−15.1 to 41.9)
≥ 65 72 22 201 70 −14.0 (−97.5 to 34.2) 13.2 (−68.4 to 55.2)
TIV (≥ 18) 49 460 92 879 −1.8 (−46.5 to 29.3) 1.9 (−63.6 to 41.2)
QIV (≥ 18) 1 460 6 879 NR NR
By influenza virus clade/lineage (all age)
B/Yamagata 106 300 495 1,273 9.1 (−16.0 to 28.8) 16.9 (−17.0 to 41.0)
H1/6b1 12 35 495 1,273 11.8 (−71.2 to 54.6) 57.9 (−2.0 to 82.6)
H3/3C2a2 
(subgroup 3) 64 49 495 1,273
−235.9 (−394.3 to 
−128.3) −95.2 (−230.6 to −15.3)
H3/3C2a1b 
(subgroup 5) 7 18 495 1,273 −0.01 (−140.9 to 58.5) 29.1 (−116 to 76.7)
H3/3C3a 3 4 495 1,273 NR NR
CI: confidence interval; LAIV4: quadrivalent live attenuated influenza vaccine; NR: not reported; QIV: quadrivalent inactivated vaccine; TIV: 
trivalent inactivated vaccine; VE: vaccine effectiveness.
a Six vaccinated cases aged between 2–17 years (three infected with influenza A(H3N2) and three infected with A(H1N1)pdm09) had no 
information on the type of vaccine (QIV or TIV) they received, so they are not included in the analyses presented in the table.
b Eight vaccinated controls aged between 2–17 years had no information on the type of vaccine (QIV or TIV) they received, so they are not 
included in the analyses presented in the table.
c Adjusted for age group, risk-group, sex, month, pilot area and surveillance scheme.
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Statistical methods
The swabbing results were analysed using a test-
negative design for VE. The odds ratio (OR) of being 
vaccinated between cases and controls was used to cal-
culate the crude VE as (1 − OR) x 100%. We performed 
a multivariable logistic regression, as previously [4], 
to adjust VE for potential confounders with influenza 
laboratory results as the outcome and influenza vac-
cination status as the linear predictor. Estimates were 
calculated adjusting for age (by < 2, 2–11, 12–17, 18–44, 
45–64 and ≥ 65 years age groups), month of onset 
of symptoms, surveillance scheme, risk-group, sex, 
and residence in an area where a primary school pro-
gramme was in place. Stratification was by age 2–17, 
18–64 and ≥ 65 years and was split by vaccine type: 
LAIV4/QIV within those aged 2–17 years and QIV/TIV 
for those aged ≥ 18 years. The effect of prior season vac-
cination was also described by calculating all the VEs 
(vaccinated both 2017/18 and 2016/17, only 2016/17 
and only 2017/18) and comparing to not vaccinated in 
either season. Decline in VE was assessed by stratifi-
cation in the model by time since vaccination (vacci-
nated within 3 months of onset and ≥ 3 months before 
onset), and also by stratification by month of onset 
(October–December/January–April). To minimise inclu-
sion of underpowered results, VE estimates where the 
upper and lower 95% CI respectively extended below 
−50% and above 80% were excluded.
Sensitivity analyses were undertaken – specifically 
including all swabs no matter how long after onset they 
had been taken; then a model including those vacci-
nated within 14 days as unvaccinated.
For statistical analysis of the seroprevalence data, 
serum titres below the detection limit (< 10) were 
assigned a numeric value of five, while sera above the 
previously determined threshold titre ≥ 40 were con-
sidered seropositive for the purpose of analysis and 
all available titres were transformed into log2titres. 
Proportions with positive titres with 95% CI by age 
group are presented. To compare A(H3N2) proportions 
positive for antigen grown in tissue culture compared 
with egg, McNemar’s chi-squared test for paired data 
was used on those samples tested by both assays.
Ethical statement
The collection of sera in the PHE SEU archive has under-
gone ethical review (REC reference: 05/Q0505/45). The 
collection and analysis of swab forms according to 
positivity was undertaken as part of routine influenza 
surveillance, with swab test-results relayed back to 
sentinel GPs to assist in clinical management. The col-
lection of the clinical data accords with routine usual 
practice in public health. Specific ethical approval was 
not necessary.
Results
Characteristics of study patients
During the study, 3,992 persons were sampled in the 
participating sentinel primary care practices and were 
tested. A total of 912 samples were excluded: the rea-
sons for study exclusion are summarised in  Figure 1, 
with swabbing more than 7 days after onset the main 
explanation. Four samples were excluded as LAIV vac-
cine virus was detected. The details of the 3,080 sam-
ples remaining stratified according to the swab result 
and by vaccination are described in  Tables 1  and  2. A 
total of 149 samples had date of vaccination imputed. 
There were 1,768 controls and 1,312 cases, of whom 
546 were influenza A (431 H3N2, 22 A unknown and 96 
(H1N1)pdm09, and 766 were influenza B, with a small 
number of multiple infections (two cases).
Influenza strains detected during the 2017/18 
season
Figure 2  shows the phylogenetic analysis of the HA 
sequences for A(H3N2) 2017/18 viruses. Genetic char-
acterisation of 778 A(H3N2) influenza viruses from all 
sources (i.e. sentinel surveillance and non-sentinel 
schemes) since week 40 showed that the majority 
(747; 96%) belong to HA genetic subclade 3C.2a, with 
199 (27%) of these 747 viruses belonging to a cluster 
within this genetic subclade designated as 3C.2a1, 
and the others belonging to other clusters in 3C.2a, 
designated as 3C.2a2, 3C.2a3 and 3C.2a4. The remain-
ing 31 A(H3N2) viruses (4%) fell in HA subclade 3C.3a. 
The northern hemisphere 2017/18 influenza A(H3N2) 
vaccine strain A/HongKong/4801/2014 belonged in 
genetic subclade 3C.2a and its relatedness to the cir-
culating strains is shown in Figure 2.
The emergence of subgroups and temporal differences 
in the distribution of viruses within both 3C.2a and 
3C.2a1 has been observed over the season in viruses 
from all sources (Figure 3). Early in the season during 
October and November, viruses in 3C.2a1, belonging 
mainly in subgroup 3C.2a1b (clade 5) accounted for 
55–60% of the A(H3N2) viruses from all sources char-
acterised genetically. During December 2017 to April 
2018, the proportion of viruses belonging to the sub-
clade 3C.2a2 (subgroup 3) become the dominant circu-
lating A(H3N2) subgroup by the end of the season. This 
season’s A(H3N2) viruses were again difficult to type 
by HI analysis with ferret antisera, and only 24 influ-
enza A(H3N2) viruses from all sources were antigeni-
cally characterised since week 40 2017, representing a 
minority of the detections and thus a potential bias in 
the available antigenic data. The viruses antigenically 
analysed showed better reactivity to ferret antiserum 
raised to tissue culture grown A/HongKong/4801/2014 
virus, than with antiserum derived from egg propa-
gated A/HongKong/4801/2014 virus. All 24 anti-
genically characterised viruses were also genetically 
characterised, with 15 belonging in genetic group 
3C.2a, including 10 within 3C.2a2 (subgroup3) and five 
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in 3C.2a1 (subgroup 4) and nine H3N2 isolates belong-
ing in subclade 3C.3a.
Genetic characterisation of 688 influenza B viruses 
from all sources was completed. A total of 682 
(99%) viruses were classified as belonging to the B/
Yamagata/16/88-lineage, genetically similar to B/
Phuket/3073/2013, the influenza B/Yamagata/16/88-
lineage component of 2017/18 northern hemisphere 
quadrivalent vaccine [14]. Six (1%) were classified 
as falling in the B/Victoria/2/87-lineage; geneti-
cally similar to B/Brisbane/60/2008 (the influenza B/
Victoria/2/87-lineage component of 2017/18 northern 
hemisphere trivalent and quadrivalent vaccines [14]) 
falling within genetic clade 1A, but with five of these 
belonging within a subgroup in clade 1A characterised 
by deletion of two amino acids in the HA. The relation-
ship of the HA genes of the circulating strains analysed 
compared with the vaccine strains is shown in  Figure 
4. A total of 489 influenza B viruses were isolated and 
antigenically characterised since week 40 2017; 485 
(99%) viruses were characterised as belonging to the 
B/Yamagata/16/88-lineage and antigenically similar 
to B/Phuket/3073/2013. Of the viruses characterised 
as belonging to the B/Victoria/2/87-lineage, one virus 
was antigenically similar to B/Brisbane/60/2008, with 
the double deletion subgroup viruses characterised as 
antigenically distinct from B/Brisbane/60/2008.
Model fitting for vaccine effectiveness 
estimation
When estimating VE, age group, sex, time period 
(defined by month of sample collection), surveillance 
scheme, risk group and primary school age pilot pro-
gramme area were adjusted for in a multivariable logis-
tic regression model. All variables that were adjusted 
for were significantly associated with a positive swab 
(Table 1). The number and proportion vaccinated for 
these variables are shown in Table 2. Only age, month 
of onset and risk-factor were confounders for the vac-
cine effects (changing the overall estimate by more 
than 5%).
The crude and adjusted VE estimates against all influ-
enza, influenza A(H3N2), influenza A(H1N1)pdm09 and 
B are shown in Table 3. For any influenza (A or B), the 
crude VE for all ages was 9.0%; the adjusted VE point 
estimate of influenza vaccine against any laboratory-
confirmed infection was 15.0% (95% CI: −6.3 to 32.0). 
Further sensitivity analyses were undertaken. Firstly, 
including all swabs no matter how long after onset 
they had been taken made less than 3% difference to 
the overall VE point estimate. Then a model including 
those vaccinated within 14 days as unvaccinated and 
including all swabs regardless of time since onset of 
symptoms found again < 3% difference to the VE point 
estimate.
Influenza A(H3N2)
The all-age adjusted VE was −16.4% (95% CI: −59.3 to 
14.9) for A(H3N2) (Table 3). Examining clade- and lin-
eage-specific estimates demonstrated overlapping CIs 
(Table 3).
Vaccine effectiveness in adults
Table 3  shows the adjusted VE against influenza 
A(H3N2) for inactivated vaccine (IIV) in 18–64 year 
olds (−14.7%; 95% CI: −72.7 to 23.8) and ≥ 65 year olds 
(16.8%; 95% CI: −74.2 to 60.3) with no evidence of sig-
nificant effectiveness in either group. In relation to vac-
cination in the prior season in those ≥ 18 years of age 
(Table 4), the VE point estimate were low in all strata 
and differences were non-significant (p value = 0.69).
Vaccine effectiveness in children
The crude and adjusted VE against A(H3N2) in chil-
dren 2–17 years of age for LAIV4 is shown in  Table 
3  with no evidence of significant effectiveness. There 
Table 4
Adjusted vaccine effectiveness estimates for influenza A(H3N2) by prior vaccination status and subtype in children 
2–17 years of age (LAIV only) and adults ≥ 18 years, United Kingdom, October 2017–April 2018 (n = 1,888)
Vaccination status Cases Controls Adjusteda VE (95% CI)
2–17 year olds (LAIV only)
Unvaccinated in 2016/17 and 2017/18 49 196 Reference
Vaccinated only in 2016/17 5 33 NR
Vaccinated only in 2017/18 10 20 −139.9 (−615.1 to 19.5)
Vaccinated in 2016/17 and 2017/18 11 20 −61.8 (−372 to 44.5)
≥ 18 year olds
Unvaccinated in 2016/17 and 2017/18 189 743 Reference
Vaccinated only in 2016/17 16 96 12.9 (−68.3 to 55.0)
Vaccinated only in 2017/18 20 76 −2.6 (−85.8 to 43.4)
Vaccinated in 2016/17 and 2017/18 94 310 −9.3 (−64.8 to 27.5)
CI: confidence interval; LAIV: live attenuated influenza vaccine; NR: not reported; VE: vaccine effectiveness.
a Adjusted for age group, risk-group, sex, month, pilot area and surveillance scheme.
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were sparse data to undertake analysis of VE for QIV 
in children. Table 4shows the influence of LAIV4 vacci-
nation in 2–17 year olds in the prior season, the differ-
ences were non-significant (p value = 0.17).
Influenza A(H1N1)pdm09
The adjusted VE was 66.3% (95% CI: 33.4 to 82.9) for 
A(H1N1)pdm09 for all ages (Table 3).
Vaccine effectiveness in adults
Table 3  shows an adjusted VE against A(H1N1)pdm09 
for inactivated vaccine (IIV) in 18–64 year olds of 69.1% 
(95% CI: 11.4 to 89.2).
Vaccine effectiveness in children
The adjusted VE against A(H1N1)pdm09 in 2–17 year 
olds for LAIV4 (Table 3) was 90.3% (95% CI: 16.4 to 
98.9). There were sparse data to undertake analysis of 
VE for QIV in children or according to prior season vac-
cine history in adults and children.
Influenza B
The overall all-age adjusted VE estimate against influ-
enza B was 24.7% (95% CI: 1.1 to 42.7) (Table 3), com-
pared with 16.9% (95% CI: −17.0 to 41.0) against only 
B/Yamagata/16/88-lineage (Table 3).
Vaccine effectiveness in adults
The adjusted VE against influenza B for 18–64 years 
olds for IIV (Table 3) was 18.2% (95% CI: −15.1 to 
41.9) and was 13.2% (95% CI: −68.4 to 55.2) for those 
≥ 65 years of age. Statistically significant protection 
was not seen in either age group. There were sparse 
data to undertake analysis of VE for QIV in adults, 
though effectiveness against TIV only was low at 1.9% 
(95% CI: −63.6 to 41.2) (Table 3). In relation to vaccina-
tion in the prior season in those ≥ 18 years of age (Table 
5), the adjusted VE estimates were similar regardless of 
prior vaccine history.
Vaccine effectiveness in children
The adjusted VE against influenza B in children 
2–17 years of age for LAIV4 was 60.8% (95% CI: 8.2 
to 83.3) (Table 3).  Table 5  shows the influence of 
prior season LAIV4 vaccination in 2–17 year olds on 
influenza B. The VE point estimate was high and similar 
regardless of prior season vaccine history.
Vaccine effectiveness by time since vaccination 
and period
Table 6 shows the adjusted VE by time since vaccination 
and period. No significant difference was observed for 
influenza B, A(H3N2) or A(H1N1)pdm09.
Detection of antibody in population serum 
samples
Antibody prevalence levels to A/Hong Kong/4801/2014 
virus were highest in the youngest (< 15 years and 
15–24 year-old) age groups for egg-grown virus for 
samples taken in summer 2017. Although egg-grown 
A(H3N2) (‘vaccine-like’ virus) antibody levels were 
lower for 25–64 year olds, they were relatively higher 
in those aged ≥ 65 years old (Figure 5A) – which is the 
most highly vaccinated population. The pattern was 
similar for samples taken in summer 2016. Overall the 
2017 seroprevalence was lower for A(H3N2) viruses 
grown in tissue culture compared with egg-grown 
across all age groups, with the mean differences by age 
group statistically significant in all ages except 15–24 
year olds (Figure 5A). The difference in seropositivity 
proportions between the two laboratory assays (tissue 
culture minus egg-grown) and their corresponding CIs 
and p values for the same age groups are given as: < 15 
years olds: −13% (95% CI: −19% to −7%, p < 0.001); 
15–24 years old: −11% (−23% to 1%, p = 0.09); 25–44 
years old: −11% (−20% to −2%, p = 0.02); 45–64 years 
old: −15% (−22% to −7%, p < 0.001); ≥ 65 years old: 
−24% (−32% to −15%, p < 0.001).
Discussion
This study finds overall a low influenza VE during a 
season that saw co-circulation of influenza B with a 
B-lineage mismatch comparing to trivalent vaccine 
and influenza A(H3N2) with a new dominant genetic 
subgroup. We demonstrate significant effectiveness 
against influenza B in children who received the quad-
rivalent influenza vaccine, but poor effectiveness 
against influenza B in adults, particularly those who 
received trivalent vaccine. No significant VE against 
A(H3N2) was seen in either adults or children regard-
less of whether vaccine was live attenuated or inac-
tivated. A number of variants of A(H3N2) circulated 
during the course of the winter, with subgroups pre-
sent at the start of the season gradually being replaced 
by different subgroups later. There was evidence of 
reduced population immunity to tissue-culture-adapted 
A(H3N2) vaccine virus, which is more representative of 
the World Health Organization (WHO) recommended 
vaccine virus compared to egg-propagated virus [15]. 
Finally, we found good protection against influenza 
A(H1N1)pdm09 in both adults and children, especially 
in those who had received live attenuated influenza 
vaccine.
There are several potential strengths to this study. The 
test-negative case–control design which is used, is a 
well-established approach to measure influenza VE in 
the UK as in many other countries. We used our stand-
ard method to provide comparability to previous sea-
son’s UK VE estimates. In addition, we triangulated VE 
and population seroprevalence data to provide impor-
tant insights into the underlying explanations for this 
season’s observations. There are some limitations to 
the study; in particular only small numbers of children, 
contraindicated LAIV, had received QIV with conse-
quent inability to provide reliable VE estimates for this 
group. Due to limited circulation, only limited VE esti-
mates for A(H1N1)pdm09 could be confidently under-
taken. Date of vaccination had to be imputed for some 
records. This is unlikely to have led to a large amount 
of misclassification as influenza circulation started 
after the majority of influenza vaccination had been 
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completed by the end of November. The only patients 
that misclassification has a non-negligible chance of 
occurring for are those with onset in October (n = 9) 
or November (n = 11) with missing vaccination date. 
This is a very small proportion of the total numbers 
vaccinated.
The end-of-season VE estimation against all labora-
tory-confirmed influenza illness presenting in primary 
care found poor effectiveness, also in adults. The 
results, which are driven by the dominance of A(H3N2) 
and B are consistent with the mid- and end-of-season 
2017/18 VE estimates published elsewhere in Europe 
and North America, many of whom experienced sea-
sons with circulation of A(H3N2) [16-18]. Our findings 
of reduced VE against influenza B are discordant with a 
number of other settings in Europe and North America 
[16-18]. This observation of reduced VE is likely to be 
due to several factors.
Notably the 2017/18 season in the UK saw early circu-
lation of influenza B with a lineage mismatch to the 
2017/18 trivalent vaccine, where influenza B cases 
observed in the UK were mainly due to viruses belong-
ing to the B/Yamagata lineage, with only a small pro-
portion of B/Victoria lineage viruses detected [8]. There 
was evidence of good protection against influenza B 
in children who received the LAIV4 vaccine. However, 
poor effectiveness against influenza B was observed 
in adults, particularly when restricted to those vac-
cinated persons who had received the 2017/18 TIV. 
Unfortunately, there were sparse data to calculate a 
reliable VE estimate for QIV only. Our finding of poor TIV 
effectiveness against influenza B in adults is consist-
ent with the epidemiology seen in the UK in 2017/18, 
with large numbers of influenza B cases hospitalised 
in highly vaccinated populations such as ≥ 65 year olds 
[8]. Our results were inconsistent with some studies 
elsewhere in Europe and Canada that did suggest a 
degree of cross-protection even though there was cir-
culation of a lineage mismatch influenza B virus. These 
latter observations may be due to prior infection or 
vaccination with a B/Yamagata lineage virus in earlier 
seasons [19]. Although we were unable to estimate QIV 
effectiveness in adults, some published data do dem-
onstrate superior effectiveness and cost-effectiveness 
of QIV compared with TIV [20,21]. More recent model-
ling by PHE based on this work has been conducted to 
understand the potential incremental benefit of QIV in 
adults in the presence of the UK childhood LAIV4 pro-
gramme [22]. This work found that, once the programme 
in children of primary school age is fully established, 
there is still benefit from preferentially using QIV in at 
risk adults < 65 years of age, including pregnant women.
We found no evidence of significant effectiveness 
against influenza A(H3N2) with either inactivated or live 
attenuated influenza vaccine, all of which are manufac-
tured on eggs. As the season progressed the majority 
of A(H3N2) viruses that were genetically characterised 
shifted from genetic subclade 3C.2a1b (subgroup 5) 
to subclade 3C.2a2 (subgroup 3) which comprised the 
majority of A(H3N2) vaccine failures observed this sea-
son. This compares to the 2016/17 UK influenza season 
that was also dominated by A(H3N2) though mainly of 
the 3C.2a1 subclade, where although effectiveness in 
the elderly was poor, there was still evidence by the 
end of the season of significant effectiveness of LAIV4 
against A(H3N2) in children and of moderate protection 
in young adults [23]. Such evidence of poorer VE against 
A(H3N2), has been well recognised in recent seasons 
[24,25]. This is a complex and multifactorial problem. 
The A(H3N2) vaccine virus component has not changed 
between 2016/17 and 2017/18, and our results suggest 
that the divergence in results between the two sea-
sons may be due to several factors including changes 
in the dominant circulating genetic subgroup. It is not 
possible to conclude if these genetic changes were 
Table 5
Adjusted vaccine effectiveness estimates for influenza B by prior vaccine status and subtype in children 2–17 years of age 
(LAIV4 only) and adults ≥ 18 years, United Kingdom, October 2017–April 2018 (n = 2,184)
Vaccination status Cases Controls Adjusteda VE (95% CI)
2–17 year olds (LAIV only)
Unvaccinated in 2016/17 and 2017/18 115 196 Reference
Vaccinated only in 2016/17 2 33 72.5 (−33.8 to 94.3)
Vaccinated only in 2017/18 4 20 NR
Vaccinated in 2016/17 and 2017/18 2 20 81.6 (10.9 to 96.2)
 ≥ 18 year olds
Unvaccinated in 2016/17 and 2017/18 411 743 Reference
Vaccinated only in 2016/17 15 96 40.0 (−13.0 to 68.1)
Vaccinated only in 2017/18 24 76 35.3 (−10.8 to 62.3)
Vaccinated in 2016/17 and 2017/18 117 310 12.1 (−24.6 to 38.0)
CI: confidence interval; LAIV: live attenuated influenza vaccine; NR: not reported; VE: vaccine effectiveness.
a Adjusted for age group, risk-group, sex, month, pilot area and surveillance scheme.
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significant antigenically. The analyses used to charac-
terise H3N2 circulating strains are limited as a result 
of the receptor binding changes in the viruses which 
have occurred over recent years [26]. Such changes 
have altered the ability to use the traditional tools for 
antigenic characterisation of circulating strains using 
ferret post-infection antisera and HI antibody reactiv-
ity, as these tests rely on receptor binding to indicator 
red cells. The limited data available so far from charac-
terisation of the antigenic profiles of circulating influ-
enza virus strains using virus neutralisation does not 
reveal major antigenic variation between the various 
H3N2 genetic subgroups. However, it is notable that 
3C.2a2 (subgroup 3) viruses have acquired the 3C.2a1 
neuraminidase (NA) gene through reassortment, which 
may contribute to overall antigenicity of the emerging 
dominant H3N2 viruses, resulting in a poorer match to 
the 2017/18 vaccine virus [27]. As the neuraminidase 
content of vaccines is not standardised, and neurami-
nidase inhibiting (NI) antibodies in the population are 
not routinely measured, it is not possible to assess 
the contribution that this evolutionary change in the 
H3N2 virus will make to overall population immunity 
and susceptibility, and therefore VE. This is an area 
which requires further detailed and systematic study, 
including an understanding of the contribution of viral 
neuraminidase to overall viral fitness and immune 
escape. Natural virus evolution seems to have been 
exacerbated further by the egg-adaption of the vaccine 
virus; with the A(H3N2) age-specific susceptibility data 
from summer 2017, showing significantly lower sero-
reactivity particularly in the elderly for the cell-derived 
A(H3N2) virus compared with the same age group for 
the egg-grown A(H3N2) virus, an observation which 
has been made elsewhere [7,28]. Tissue culture grown 
vaccine virus strains are considered more representa-
tive of the circulating virus strains which are recovered 
from human respiratory tract [15]. Detailed follow-up 
investigations of the molecular basis of the differences 
are required from this observation. However, it does 
highlight the potential value of seroprevalence surveys 
to identify possible susceptibility gaps in the popula-
tion. Further work is required to disentangle the rela-
tive contribution of these different factors including 
Table 6
Adjusted vaccine effectiveness estimates for influenza by influenza subtype and time since vaccination and period, United 
Kingdom, October 2017–April 2018 (n = 3,080)
Time elapsed since vaccination at 
symptom onset or period of symptom 
onset
Cases Controls Adjusteda VE 
 
(95% CI)Vaccinated Unvaccinated Vaccinated Unvaccinated
Influenza A and B
3 months 163 969 297 1,273 18.7 (−7.7 to 38.6)
≥ 3 months 180 969 198 1,273 10.4 (−19.9 to 33.0)
Oct to Dec 83 291 203 721 −7.3 (−65.4 to 30.4)
Jan to Apr 260 678 292 552 20.3 (−3.9 to 38.9)
Influenza A
3 months 89 375 297 1,273 −1.3 (−44.7 to 29.1)
≥ 3 months 83 375 198 1,273 9.5 (−32.4 to 38.1)
Oct to Dec 48 129 203 721 −43.4 (−157.0 to 20.0)
Jan to Apr 124 246 292 552 14.9 (−19.8 to 39.5)
Influenza A(H3N2)
3 months 78 280 297 1,273 −17.6 (−73.7 to 20.4)
≥ 3 months 73 280 198 1,273 −15.4 (−73.4 to 23.2)
Oct to Dec 44 103 203 721 −71.0 (−227.4 to 10.7)
Jan to Apr 107 177 292 552 −3.6 (−49.7 to 28.3)
Influenza H1N1pdm09
3 months 10 78 297 1,273 47.9 (−15.1 to 76.5)
≥ 3 months 8 78 198 1,273 78.8 (40.2 to 92.5)
Oct to Dec 4 19 203 721 NR
Jan to Apr 14 59 292 552 71.7 (36.8 to 87.4)
Influenza B
3 months 75 594 297 1,273 33.5 (5.2 to 53.4)
≥ 3 months 97 594 198 1,273 16.1 (−18.8 to 40.8)
Oct to Dec 36 162 203 721 19.3 (−40.3 to 53.6)
Jan to Apr 136 432 292 552 25.9 (−1.8 to 46.0)
CI: confidence interval; NR: not reported; VE: vaccine effectiveness
a Adjusted for age group, risk-group,  sex, month, pilot area and surveillance scheme.
15www.eurosurveillance.org
yearly vaccination and immunosenescence. Though 
these results support the need for more effective inter-
ventions against A(H3N2), particularly for older people, 
where the burden of A(H3N2) is most notable [29], but 
also children, where the programme is intended to pro-
vide both direct protection to the children themselves, 
and by reducing their rates of infection, indirectly pro-
tect others in the population. WHO has recommended 
that the A(H3N2) component of the 2018/19 vaccine 
is updated to the A/Singapore/INFIMH-16–0019/2016 
(H3N2)-like virus and the UK has preferentially recom-
mended adjuvanted vaccine for the elderly in 2018/19, 
which is likely to enhance and increase the breadth of 
the immune response against A(H3N2). Finally, cell-
based influenza vaccines, which avoid the issue of 
egg-adaption are now being used in North America and 
are now licensed for use in the UK in 2019/20. Indeed 
VE results from the 2017/18 season in the US suggest 
such vaccines offer significantly better protection com-
pared with traditional egg-based, non-high dose vac-
cines in ≥ 65 year olds [30].
The present study does report significant LAIV4 effec-
tiveness for children 2–17 years of age against influ-
enza A(H1N1)pdm09. These results are particularly 
encouraging in the light of the temporary recommen-
dation to not use LAIV4 in the US following the find-
ing of reduced VE in 2015/16 [5]. The US results of no 
significant effectiveness against A(H1N1)pdm09 were 
at odds with those seen in several other countries that 
had used LAIV4 in 2015/16, including the UK [6,31], 
though all had noted lower effectiveness of LAIV4 
against A(H1N1)pdm09 compared with IIV in 2015/16. 
One emerging hypothesis suggests this might relate to 
reduced replicative ability of the A(Bolivia/559/2013) 
(H1N1)pdm09 vaccine strain in LAIV4 [31], whereby 
this strain was updated to the A(Slovenia/2903/2015) 
(H1N1)pdm09 strain for the 2017/18 season. Recently 
presented results from the LAIV manufacturer in the US 
indicate more encouraging shedding and immunogenic-
ity data of this new strain in young children compared 
with A/Bolivia/559/2013 [32]. The results in this study 
of good effectiveness against A(H1N1)pdm09 supports 
the ongoing roll-out of the UK paediatric influenza vac-
cine programme, although the reduced A(H3N2) effec-
tiveness seen this season (due to likely egg-adaption) 
still needs to be addressed.
In summary, this work demonstrates a lack of signifi-
cant effectiveness against A(H3N2) in all age groups 
possibly related to several factors most notably egg-
adaption of the vaccine virus combined with the emer-
gence of a new A(H3N2) subgroup. It is hoped that the 
impact of A(H3N2) will be mitigated by the updating 
of the A(H3N2) vaccine virus strain in 2018/19 and the 
availability of newly licensed adjuvanted, high-dose 
and cell-based vaccines in the UK. The result of lower 
effectiveness of inactivated trivalent vaccine against 
influenza B in adults seems most likely related to the 
B lineage mismatch this season. The introduction of 
quadrivalent influenza vaccine for adults in the UK in 
2018/19 is intended to help to improve protection [33]. 
The VE results for both influenza B and A(H1N1)pdm09 
in children are encouraging – though the poor perfor-
mance against A(H3N2) this season will need to be 
monitored carefully.
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